Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
Department of Cardio and Organ Systems, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
J Exp Med. 2020 May 4;217(5). doi: 10.1084/jem.20191660.
Failure of remyelination underlies the progressive nature of demyelinating diseases such as multiple sclerosis. Macrophages and microglia are crucially involved in the formation and repair of demyelinated lesions. Here we show that myelin uptake temporarily skewed these phagocytes toward a disease-resolving phenotype, while sustained intracellular accumulation of myelin induced a lesion-promoting phenotype. This phenotypic shift was controlled by stearoyl-CoA desaturase-1 (SCD1), an enzyme responsible for the desaturation of saturated fatty acids. Monounsaturated fatty acids generated by SCD1 reduced the surface abundance of the cholesterol efflux transporter ABCA1, which in turn promoted lipid accumulation and induced an inflammatory phagocyte phenotype. Pharmacological inhibition or phagocyte-specific deficiency of Scd1 accelerated remyelination ex vivo and in vivo. These findings identify SCD1 as a novel therapeutic target to promote remyelination.
脱髓鞘疾病(如多发性硬化症)具有进行性特征,其根本原因是髓鞘修复失败。巨噬细胞和小胶质细胞在脱髓鞘病变的形成和修复中起着至关重要的作用。在这里,我们发现髓磷脂摄取会暂时使这些吞噬细胞向有利于疾病缓解的表型倾斜,而髓磷脂的持续细胞内积累则会诱导促进病变的表型。这种表型转变受酰基辅酶 A 去饱和酶 1(SCD1)的控制,该酶负责饱和脂肪酸的去饱和作用。SCD1 产生的单不饱和脂肪酸减少了胆固醇外排转运蛋白 ABCA1 的表面丰度,进而促进脂质积累并诱导炎症性吞噬细胞表型。Scd1 的药理学抑制或吞噬细胞特异性缺失可加速体外和体内的髓鞘再生。这些发现确定 SCD1 是促进髓鞘再生的新的治疗靶点。